priors.science/reviews/anti-amyloid-antibodies

Anti Amyloid Antibodies

The current evidence on 11 claims, ordered from most established to most contested. Each score is the panel’s evidence certainty: how firmly the literature supports the claim as stated.

12claims tracked

11assessed

146primary papers reviewed

26 Oct 2026latest evidence review

5 Established · 1 Likely · 3 Uncertain · 2 Doubtful | four-reviewer panel · PICO Framework

ClaimStandingEvidence certaintyCorpus

Lecanemab and donanemab clear amyloidAmyloidEstablished92%20

Lecanemab slows decline in early Alzheimer's diseaseEfficacyEstablished88%21

Donanemab slows decline in early Alzheimer's diseaseEfficacyEstablished86%23

APOE4 homozygotes face higher amyloid-related imaging abnormality riskSafetyEstablished86%18

Anti-amyloid drugs are disease-modifyingCmeLikely82%24

Amyloid clearance and clinical outcomesAmyloidUncertain60%19

Aducanumab clinical benefit unprovenEfficacyUncertain58%17

Amyloid pathology required for benefitSelectionUncertain58%20

Low tau burden predicts better responseSelectionDoubtful33%20

Anti-amyloid effects exceed minimal clinically important differenceCmeDoubtful32%17

Track Anti Amyloid Antibodies.

These claims are re-checked against new research as it is published. Track this topic for the full review, including each claim’s challenge and the papers behind it.

Track this topic →

Standing: what the evidence certainty means

Established≥ 85%Strong, consistent evidence. Unlikely to change.

Likely70–84%Well supported, with some gaps or indirect evidence.

Uncertain50–69%Mixed or limited evidence. Genuinely open.

Doubtful30–49%Little support; the weight of evidence leans against it.

Refuted< 30%The evidence contradicts it. Confidently false as stated.

A standing changes only when the score moves past a boundary by more than 4 points, the re-scoring noise floor; a score within 4 points of a boundary keeps its previous standing.